[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"transient-ischemic-attack-due-to-embolism\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:transient-ischemic-attack-due-to-embolism":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":28,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":5},"100648562","long-term-outcomes-after-percutaneous-patent-foramen-ovale-closure-severance-pfo-registry-100648562",false,"NCT07724171","Long-term Outcomes After Percutaneous Patent Foramen Ovale Closure (Severance PFO Registry)","Long-term Clinical Outcomes and Prognostic Factors After Percutaneous Patent Foramen Ovale Closure: A Retrospective Cohort Study With Prospective Registry Extension","Inclusion Criteria:\n\n1. Age 19 years or older\n2. Percutaneous patent foramen ovale closure\n3. Retrospective cohort: closure performed between 2010 and March 2026, with at least one post-procedural agitated saline transthoracic echocardiography\n4. Prospective cohort: closure performed after institutional review board approval, with written informed consent\n\nExclusion Criteria:\n\n1. Atrial septal defect closure (defect other than patent foramen ovale)\n2. Device embolization or device removal\n3. Echocardiographic image quality inadequate for assessment of shunt\n4. Prospective cohort: refusal of informed consent","ALL","19 Years",{"count":19,"type":20},400,"ESTIMATED","OBSERVATIONAL","Patent foramen ovale (PFO) is a congenital interatrial communication present in about one quarter of the general population and is recognized as a major cause of cryptogenic stroke. Percutaneous PFO closure reduces recurrent stroke, but a residual right-to-left shunt persists in 20 to 40 percent of patients after device implantation. Long-term data on device performance, the evolution of residual shunt over time, new-onset atrial fibrillation and other prognostic factors remain limited.\n\nThis single-center registry evaluates the long-term efficacy and safety of percutaneous PFO closure and identifies the clinical, anatomical, procedural and pharmacological factors associated with clinical and echocardiographic outcomes. The registry combines a retrospective cohort of patients treated at Severance Hospital between 2010 and March 2026 with a prospective registry extension that enrolls patients undergoing PFO closure after institutional review board approval, with follow-up for up to 119 months.\n\nClinical outcomes include recurrent ischemic stroke or transient ischemic attack, all-cause death, device-related complications and new-onset atrial fibrillation. Echocardiographic outcomes are assessed by serial agitated saline transthoracic echocardiography, which allows the presence, grade and longitudinal trajectory of residual shunt to be characterized.",[24,25,26,27],"Patent Foramen Ovale","Cryptogenic Stroke","Transient Ischemic Attack Due to Embolism","Atrial Fibrillation",[29,30,31,32,33,34,35,36,37,38],"patent foramen ovale (PFO)","percutaneous closure","residual shunt","right-to-left shunt","agitated saline contrast echocardiography","transthoracic echocardiography (TTE)","recurrent stroke","transient ischemic attack (TIA)","registry","prognostic factors","RECRUITING","2026-07-21",{"date":42,"type":43},"2026-07-23","ACTUAL",{"date":45,"type":43},"2026-06-05",{"date":47,"type":20},"2036-05-04",{"name":49,"class":50},"Yonsei University","OTHER"]